首页> 外文期刊>BMC Nephrology >Contrast-induced acute kidney injury and adverse clinical outcomes risk in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis
【24h】

Contrast-induced acute kidney injury and adverse clinical outcomes risk in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis

机译:对比诱导急性肾损伤和急性冠状动脉综合征患者经皮冠状动脉介入的患者的不良临床结果风险:荟萃分析

获取原文
           

摘要

Recent studies have shown associations between contrast-induced acute kidney injury (CI-AKI) and increased risk of adverse clinical outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI); however, the estimates are inconsistent and vary widely. Therefore, this meta-analysis aimed to evaluate the precise associations between CI-AKI and adverse clinical consequences in patients undergoing PCI for ACS. EMBASE, PubMed, Web of Science? and Cochrane Library databases were systematically searched from inception to December 16, 2016 for cohort studies assessing the association between CI-AKI and any adverse clinical outcomes in ACS patients treated with PCI. The results were demonstrated as pooled risk ratios (RRs) with 95% confidence intervals (CI). Heterogeneity was explored by subgroup analyses. We identified 1857 articles in electronic search, of which 22 (n?=?32,781) were included. Our meta-analysis revealed that in ACS patients undergoing PCI, CI-AKI significantly increased the risk of adverse clinical outcomes including all-cause mortality (18 studies; n?=?28,367; RR?=?3.16, 95% CI 2.52-3.97; I2?=?56.9%), short-term all-cause mortality (9 studies; n?=?13,895; RR?=?5.55, 95% CI 3.53-8.73; I2?=?60.1%), major adverse cardiac events (7 studies; n?=?19,841; RR?=?1.49, 95% CI: 1.34-1.65; I2?=?0), major adverse cardiovascular and cerebrovascular events (3 studies; n?=?2768; RR?=?1.86, 95% CI: 1.42-2.43; I2?=?0) and stent restenosis (3 studies; n?=?130,678; RR?=?1.50, 95% CI: 1.24-1.81; I2?=?0), respectively. Subgroup analyses revealed that the studies with prospective cohort design, larger sample size and lower prevalence of CI-AKI might have higher short-term all-cause mortality risk. CI-AKI may be a prognostic marker of adverse outcomes in ACS patients undergoing PCI. More attention should be paid to the diagnosis and management of CI-AKI.
机译:最近的研究表明,对比致急性肾损伤(CI-AKI)之间的关联以及急性冠状动脉综合征(ACS)患者经皮冠状动脉干预(PCI)的患者的不良临床结果的风险增加;但是,估计是不一致的并且很大。因此,该荟萃分析旨在评估CI-AKI与ACS接受PCI患者的不良临床后果之间的精确关联。 Embase,PubMed,科学网?从2006年12月16日,在2016年12月16日开始进行Cochrane图书馆数据库,用于评估CI-AKI与用PCI治疗的ACS患者的任何不良临床结果之间的关系。结果被证明为汇集的风险比(RRS),置信度为95%置信区间(CI)。亚组分析探索了异质性。我们在电子搜索中确定了1857篇文章,其中包括22(n?=?32,781)。我们的荟萃分析显示,在接受PCI的ACS患者中,CI-AKI显着增加了不良临床结果的风险,包括全导致死亡率(18项研究; N?=?28,367; RR?= 3.16,95%CI 2.52-3.97 ; I2?=?56.9%),短期全导致死亡率(9研究; N?=?13,895; RR?=?5.55,95%CI 3.53-8.73; I2?= 60.1%),主要的不良心脏事件(7研究; N?= 19,841; RR?= 1.49,95%CI:1.34-1.65; I2?=?0),主要不良心血管和脑血管事件(3研究; N?= 2768; RR? =?1.86,95%CI:1.42-2.43; I2?=?0)和支架再狭窄(3研究; N?= 130,678; RR?= 1.50,95%CI:1.24-1.81; I2?=?0 ), 分别。亚组分析表明,具有前瞻性队列设计,更大的样本量和CI-AKI较低的研究可能具有更高的短期内所有死亡率风险。 CI-AKI可能是接受PCI的ACS患者的不良结果的预后标志物。应更多地关注CI-AKI的诊断和管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号